Home
Categories
EXPLORE
True Crime
Comedy
Business
Society & Culture
Health & Fitness
Sports
Technology
About Us
Contact Us
Copyright
© 2024 PodJoint
00:00 / 00:00
Podjoint Logo
US
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts126/v4/7d/9b/d3/7d9bd3f3-fa07-0f5b-2e8e-05a73f5c5c21/mza_11786603917402333547.jpg/600x600bb.jpg
Future of Drug Discovery
Murat Tunaboylu
17 episodes
6 days ago
The future of healthcare depends on a better-connected community. In the Future of Drug Discovery (FODD) series, we bring innovators together from academia and industry to forge new neural paths in our collective brain. Our hope is to catalyse interactions to form the next-generation treatments.
Show more...
Life Sciences
Science
RSS
All content for Future of Drug Discovery is the property of Murat Tunaboylu and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
The future of healthcare depends on a better-connected community. In the Future of Drug Discovery (FODD) series, we bring innovators together from academia and industry to forge new neural paths in our collective brain. Our hope is to catalyse interactions to form the next-generation treatments.
Show more...
Life Sciences
Science
https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_episode/21629757/21629757-1694770221820-b069e54bb322f.jpg
Abhishek Pandey - Machine Learning Blueprints for Pharma Discovery Breakthroughs (FODD #11)
Future of Drug Discovery
27 minutes 54 seconds
1 year ago
Abhishek Pandey - Machine Learning Blueprints for Pharma Discovery Breakthroughs (FODD #11)

In this talk, Murat speaks with Abhishek Pandey, Principle Research Scientist and Pharma Discovery Group Lead at AbbVie. 


Abhishek currently leads RAIDERS, a Pharma Discovery group integrating machine learning across all of AbbVie's working groups to augment drug discovery capabilities. Abhishek's groups work spans cheminformatics, imaging research, multi-omics, as well as the computation behind many of AbbVie's current partnerships and collaborations. 


We'll be exploring how the machine learning group is transforming the processes across multiple working groups at the pharmaceutical giant, AbbVie. We'll also be unravelling the story of how Abhishek began his pioneering work at AbbVie.


You will learn:

  • About Abhishek's strategy for bridging chemistry, biology and computer science expertise to integrate machine learning across AbbVie's pharma discovery processes.
  • About Abhishek's vision for the future of drug discovery, as we explore the pressing needs of the pharmaceutical industry from both a technical and social standpoint.


About Abhishek:

Abhishek started his career as a software engineer at Toshiba. Following this, Abhishek began his PhD in medical engineering and image processing at the University of Arizona. This led Abhishek to become a core member of the precision medicine AI team at Tempus, developing ways to improve cancer imaging pipelines to help oncologists detect cancers more efficiently. Abhishek then joined AbbVie, where he founded the machine learning / deep learning team - the influence of which has expanded across the entire company. 


Things mentioned:

  • Abhishek Pandey⁠, Principle Research Scientist and Pharma Discovery Group Lead at ⁠AbbVie⁠.
  • RAIDERS: Pharma Discovery and Developmental Sciences team at AbbVie.
  • Google
  • Meta
  • Toshiba
  • Tempus Labs (now Tempus).
  • PADME (Protein And Drug Molecule interaction prEdiction), a framework based on Deep Neural Networks, to predict real-valued interaction strength between compounds and proteins.
  • NeurIPS Conference (Conference on Neural Information Processing Systems)
  • InSitro
  • Facebook

Additional Materials: 

  • ⁠⁠⁠⁠⁠Watch the recording of the live event! ⁠https://www.youtube.com/watch?v=F9kADawRPOs


First time hearing about Antiverse?

Antiverse is an artificial intelligence-driven techbio company that specialises in antibody design against difficult-to-drug targets, including G-protein coupled receptors (GPCRs) and ion channels. Headquartered in Cardiff, UK and with offices in Boston, MA, Antiverse combines state-of-the-art machine learning techniques and advanced cell line engineering to develop de novo antibody therapeutics. With a main focus on establishing long-term partnerships, Antiverse has collaborated with two top 20 global pharmaceutical companies. In addition, they are developing a strong internal pipeline of antibodies against several challenging drug targets across various indications.

For more information, please visit https://www.antiverse.io


Never miss a future event!

We'll notify you when there's a new event scheduled. Fill out ⁠this form⁠ to sign up for marketing communications from Antiverse. We post about upcoming events on LinkedIn and Twitter.

LinkedIn: ⁠https://www.linkedin.com/company/antiverse/⁠

Twitter (x.com) : ⁠https://twitter.com/AntiverseHQ

Future of Drug Discovery
The future of healthcare depends on a better-connected community. In the Future of Drug Discovery (FODD) series, we bring innovators together from academia and industry to forge new neural paths in our collective brain. Our hope is to catalyse interactions to form the next-generation treatments.